Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2007

View Archived Issues

HDAC inhibitors suppress inflammation in murine contact hypersensitivity models

Noncytotoxic streptolysin O analogue may promote wound healing

Positive preclinical results for novel dual CCR3 and histamine H1 receptor antagonist

Resverlogix begins ApoA-I research program for cognitive function disorders

New HIV-1 protease inhibitor may be useful against multi-drug resistant HIV-1

Positive interim findings for Riquent in phase III lupus trial

AL-108 meets phase Ib trial objectives

Orphan Europe acquires rights to Cystadane

Urso receives Japanese approval for hepatic function in chronic hepatitis

Phase III planned for Diamyd in type 1 diabetes

Azixa begins phase II for glioblastoma multiforme

Enrollment completed in pivotal Gabapentin GR study

Arpida adds novel antibiotic AR-2474 to its preclinical pipeline

Inhaled TPI ASM8 begins expanded phase II study in chronic allergic asthma

Phase IIa celiac disease study of AT-1001 completes enrollment

Additional data reported from pivotal M6G study

Neoprobe updates clinical programs

sBLA filed for Evicel for general hemostasis in surgery

HHS cancels acute radiation syndrome RFP

Phase II ralfinamide study in neuropathic pain completes enrollment

N-69: a novel nucleoside analogue potentially useful in melanoma therapy

Claudins validated as targets in ovarian cancer

sNDA filed for Tamiflu 30 mg and 45 mg capsules

Recent AnorMED and Merck patents report novel agents for HIV infection

Novel therapeutic agents for cardiovascular disorders disclosed in recent Pfizer and Novartis patent

Recent IRM patent describes new treatment option for thrombocytopenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.